Comparison of the clinical efficacy and safety of recombinant tissue type plasminogen activator and urokinase in the treatment of acute myocardial infarction

Abstract

Objective To investigate the clinical efficacy and safety of recombinant tissue type plasminogen activator(rr- PA)and urokinase(UK)in the treatment of acute myocardial infarction(AMI). Methods According to the digital table, 128 patients with AMI were randomly divided into two groups,64 cases in each group. The control group adopted UK intravenous thrombolytic therapy, while the observation group adopted rr - PA intravenous thrombolytic therapy. The recanalization condition at different time after thrombolytic therapy, the incidence rate of cardiovascular events and death rate were compared between the two groups. Results The recanalization rate at 30min,60min and 120min after thrombolysis of the observation group were 29.69%, 59.38% and 93.75%, respectively, which were significantly higher than 14.06%,35.94% and 68.75% of the control group(χ2= 6.34,7.01,7.45,all P< 0.05); The incidence rate of cardiovascular events and mortality rate of the observation group after thrombolytic therapy were 17.19% and 4.64%,respectively, which were significantly lower than 40.63% and 12.50% of the control group(χ2= 7.83,7.62,all P<0.05). Conclusion Recombinant tissue type plasminogen activator intravenous thrombolytic therapy has significant effect in the treatment of acute myocardial infarction after thrombolysis, which can reduce the incidence of cardiovascular events and mortality, with good clinical application value. Key words: Myocardial infarction; Tissue plasminogen activator; Urokinase-type plasminogen activator